PI3K/Akt/mTOR Signaling Pathway and the Biphasic effect of Arsenic in Carcinogenesis

Qiao Yi Chen and Max Costa

Department of Environmental Medicine, New York University School of Medicine,
Tuxedo NY, USA
Running title: Arsenic carcinogenesis: PI3K/Akt/mTOR Signaling Pathway

Corresponding Author:

Professor Max Costa
Department of Environmental Medicine
New York University School of Medicine
57 Old Forge, Tuxedo NY, 10987
Telephone: 845-731-3515
Fax: 845-351-2118
Email: Max.Costa@nyumc.org

Number of pages: 46
Word count: 4,336
Number of tables: 2
Number of figures: 1
Number of references: 134
Number of words – Abstract: 190
Number of words – Introduction: 412
Number of words – Discussion: 371

Abbreviations:

| Abbreviation | Description                      |
|--------------|----------------------------------|
| ACAP1        | Arf-GAP with coiled-coil         |
| AKT          | Protein kinase B                 |
| APL          | Acute promyelocytic leukemia     |
| AP-1         | Activator protein 1              |
| ATO          | Arsenic trioxide                 |
| As2S2        | Arsenic disulfide                |
| Abbreviation | Description |
|--------------|-------------|
| BAX | Bcl-2-associated X protein |
| B-CLL | B-cell chronic lymphocytic leukemia |
| BEAS-2B | Human bronchial epithelial cells |
| EGF | Epidermal growth factor |
| EGFR | Epidermal growth factor receptor |
| FOXO | Forkhead box O |
| HBEC | Human bronchial epithelial cells |
| HCS-2/8 | Human chondrocyte cell |
| HIF-1 | Hypoxia-inducible factor 1 |
| HIF-1a | Hypoxia-inducible factor 1-alpha |
| HOS | Human osteosarcoma cell |
| HT-29 | Human colorectal adenocarcinoma cell |
| HUC1 | Normal human bladder cells |
| H3K9ac | Histone H3 Lysine K9 acetylation |
| H4K16ac | Histone H4 Lysine K16 acetylation |
| IARC | International Agency for Research on Cancer |
| IGF-1 | Insulin-like growth factor-1 |
| IKK | IκB kinase |
| IL-6 | Interleukin 6 |
| JB6Cl41 | Mouse epidermis-derived cells |
| JNK | c-Jun N-terminal kinase |
| MG-63 | Human osteosarcoma cell |
| mTOR | Mammalian target of rapamycin |
| mTORC1 | mTOR complex 1 |
| NFκB | Nuclear factor kappa-light-chain-enhancer of activated B cells |
| OUMS-27 | Human chondrosarcoma cell |
| Pak1 | P21/Cdc42/Rac1-Activated Kinase 1 |
| PDK1 | Phosphoinositide-dependent kinase |
| PHLPP | Pleckstrin homology domain leucine-rich repeat protein phosphatase |
| PIP2 | Phosphatidylinositol-3,4,5-triphosphate |
| PIP3 | Phosphatidylinositol-4,5-bisphosphate |
Abstract

Arsenic is a naturally occurring ubiquitous metalloid found in the Earth’s crust. In its inorganic form, Arsenic is highly toxic and carcinogenic, and is widely found across the globe and through out the environment. As an International Agency for Research on Cancer (IARC) defined Class I human carcinogen, arsenic has been found to cause multiple human cancers including liver, lung, urinary bladder, skin, kidney, and prostate. Mechanisms of arsenic-induced carcinogenesis remain elusive and this review specifically focuses on the role of PI3K/AKT/mTOR pathway in promoting cancer development. In addition to exerting potent carcinogenic responses, arsenic is also known for its therapeutic effects against acute promyelocytic leukemia. Current literature suggests that arsenic is capable of achieving both therapeutic as well as carcinogenic effects, and this review serves to examine the paradoxical effects of arsenic, specifically through the PI3K/AKT/mTOR pathway. Furthermore, A comprehensive review of current literature reveals an imperative need for future studies to establish and pinpoint the exact conditions for which arsenic can, and through what mechanisms it is able to differentially regulate the PI3K/AKT/mTOR pathway in order to maximize the therapeutic and minimize the carcinogenic properties of arsenic.
Introduction

Arsenic is a naturally occurring ubiquitous metalloid found in the Earth’s crust. In its inorganic form, Arsenic is highly toxic and carcinogenic, and is widely found across the globe and throughout the environment. Along with natural corrosion of rocks and minerals, anthropogenic sources of contamination such as burning of fossil fuels, mining, and application of arsenical pesticides further aggravate arsenic-elicited public health issues, which first gained recognition beginning in the 1990s. Today nearly 200 million people are exposed to arsenic at levels above the World Health Organization’s recommended limit of 10 parts per billion (ppb). Startling levels of arsenic have been found around various regions around the world, including the French Mediterranean costal areas, Bangladesh, China, United States, Mexico, etc. (Chen & Costa 2017). In the United States, excessive amounts of arsenic in drinking water have been found in the New England, Western, and Midwestern regions (Carpenter and Jiang 2013). In fact, more than 70 countries documenting arsenic contamination reported levels up to 5000 ppb (Shankar et al. 2014). Arsenic is known to pollute the water system, but the route of exposure is not limited to drinking water. Adding to the extensity of arsenic’s prevalence, toxic dust of this metalloid can be found in common occupational settings such as copper smelters and areas neighboring the smelter (Axelson et al. 1978; Enterline et al. 1987; Carpenter and Jiang 2013).

High concentrations of arsenic can elicit rapid toxic effects resulting in death. As a matter of fact, arsenic is infamously known as the “Poison of the Kings.” On the other hand, non-lethal doses of chronic arsenic exposure can elicit potent carcinogenic effects. As an International Agency for Research on Cancer (IARC) defined Class I human
carcinogen, arsenic has been found to cause multiple human cancers including liver, lung, urinary bladder, skin, kidney, and prostate (Naujokas et al., 2013). Chen et al. 2011 reported that at levels between 10-300 ppb, serious conditions such as cardiovascular and neurological diseases, skin lesions, hepatic and renal dysfunctions have been reported. An estimated 100 million people are chronically exposed to more than 50 ppb of arsenic via drinking water (Moon et al. 2012). And in regards to the wide-range health effects of arsenic exposure, tremendous amounts of scientific efforts have been invested in elucidating the mechanisms of arsenic-induced toxicity and carcinogenicity. While current studies suggest the mechanisms are manifold, this review will specifically focus on the role of the PI3K/AKT/mTOR, a prominent cellular signaling pathway, in arsenic-induced carcinogenesis.
Potential Mechanisms of Arsenic-induced Carcinogenicity

The processes of cancer initiation, promotion, and progression are overwhelmingly complex, and arsenic-induced carcinogenesis may occur through multiple mechanisms. Current evidence suggests that arsenic works through both genotoxic and cytotoxic, as well as epigenetics pathways, which further complicates the quest to mitigate arsenic-associated diseases and cancers. Research suggests that reactive oxygen species (ROS) generated through arsenic metabolism can contribute to cancer initiation and promotion (Barchowsky et al. 1996; Liu and Jan, 2000; Lynn et al. 2000; Huang et al. 2004). Reactive oxygen species are effective at modifying the DNA by inducing base-pair mutations, insertions, deletions, etc. (Rossman et al. 1980; Huang et al. 2004). DNA damage of essential tumor suppressor genes, can give rise to carcinogenesis. ROS have also been suggested to disturb important cytoplasmic and nuclear signal transduction pathways, both of which are vital for controlling gene expression (Sen and Packer 1996; Lander 1997; Li et al. 1998; Huang et al. 2004).

Cellular response to activation or inhibition of specific gene transcription are stimulated through extracellular signals which are transmitted through the cell plasma membrane, passed along a chain of intracellular signaling molecules to regulatory transcription factors, which consist of proteins that recognize specific DNA sequences and initiate transcription (Huang et al. 2004). Note, that basal transcription as well as endogenous stressor-induced transcription can also occur. In the case of malignant cell transformation, a variety of signaling pathways and transcription factors such as AP-1, NFκB, regulate the expression of genes that carry out cell proliferation, differentiation, and transformation (Huang et al., 1999; Huang et al., 2004; Wang et al. 1996).
evidence also suggests that arsenic can exert its carcinogenic effects through disrupting important signal transduction pathways (Huang et al. 1999; Huang et al. 2004; Snow, 1992). One prominent example is the PI3K/AKT/mTOR pathway. Due to the many important roles of PI3K, AKT, and mTOR in cell survival, cellular physiology, and pathologic alterations; perturbations of this pathway have been shown to elicit cancers of the breast, colon, neck, ovary, and lung (Levine 2007; Bartholomeusz and Gonzalez-Angulo 2012; Kandoth et al. 2013; Li and Wang 2014; Guimaraes et al. 2015; Tai et al 2017). Alterations in the PI3K/AKT/mTOR pathway can be caused by various factors including genetic mutations, Hepatitis C virus, chemical toxicants such as heavy metals, and physiological products including free fatty acids and interleukin (IL)-6 (Li and Wang 2014). Chemical toxicants such as arsenic, mercury, cadmium, vanadate, and nicotine have been shown to induce malignant cell transformation through the PI3K/AKT/mTOR pathway (Gao et al. 2002; West et al. 2003; Gao et al. 2004; Wang et al. 2009; Jing et al. 2012; Rauch et al. 2012; Li and Wang 2014; Roy et al. 2014). Multiple studies demonstrate that this signaling cascade is often found disrupted after chronic arsenic exposure (Jiang and Liu et al., 2009; Carpenter et al. 2011; Carpenter and Jiang 2013). This review provides a comprehensive perspective on arsenic-induced carcinogenesis focusing on the PI3K/AKT/mTOR pathway.
Phosphoinositide 3-kinase

Phosphoinositide 3-kinase (PI3K) activity can be activated by various growth factor receptors and oncogenes. In fact, elevated PI3K signaling is regarded as a distinct hallmark of cancer (Fruman et al., 2017). PI3K family members consist of heterodimeric enzymes, and are divided based on structure, function, and substrate specificity, into three major classes. In almost all tissue types studied to date, PI3K signaling has been found to have important implications in a variety of physiological processes. And notably, PI3K family members are also involved in an extensive range of cellular regulatory processes such as cell proliferation, migration, and metabolism (Fruman et al., 2017). Consequently, alterations in the PI3K signaling pathway can lead to a variety of human diseases including cardiovascular, diabetes, as well as neurological and immunological disorders (Fruman et al., 2017). Furthermore, as demonstrated using cancer genomic analyses, PI3K gene mutations are frequently found in human tumors (Samuels et al., 2004).

Class I PI3Ks have the unique ability to catalyze the phosphorylation of phosphatidylinositol-4,5-bisphosphate (PIP2) into phosphatidylinositol-3,4,5-triphosphate (PIP3), a secondary messenger and mediator of PI3K activity, specific for the recruitment of cytoplasmic proteins to the endo- or plasma membranes (Czech, 2000; Rameh and Cantley, 1999). Studies suggest that PIP3 is critical to PI3K related oncogenicity, elevated levels of PIP3 are frequently found in cancer cells, thus class I, rather than II and III, are specifically linked to cancer development (Fruman et al., 2017; Zhao and Vogt 2008). Within Class I, there are four catalytic isoforms: p110a, b, g, and d, encoded by PIK3CA, PIK3CB, PIK3CG, and PIK3CD, respectively. In general, Class I PI3Ks are
stimulated by various upstream activators such as receptor-coupled tyrosine kinase (RTK), heterotrimeric G proteins, and small Ras-related GTPases (Fruman et al., 2017). In the event of RTK activation, two PI3K subunits, PI3KR1 (PI3K p85) and PI3KCA (PI3K p110) are recruited to form an active PI3K complex, which will then proceed to phosphorylate PIP2 to form PIP3 (Manning and Cantley, 2007). PI3K signaling is negatively regulated by lipid phosphatases such as tumor suppressor PTEN, which can rapidly remove the 30-phosphate on PIP3 and terminate PI3K signaling. Many human tumors are associated with loss of PTEN function as well as elevated levels of PIP3, which are now two of the most frequently altered gene functions in human cancers (Fruman et al., 2017; Lawrence et al., 2014).
**Protein Kinase B (AKT)**

Members of the Protein Kinase B (AKT), serine/threonine kinase family, exist in three main isoforms: Akt1, Akt2, and Akt3, and are common downstream effectors of PI3K signaling pathway (Fresno et al., 2004). AKT is a master regulator of tumor cell invasion, migration, and metastasis, capable of phosphorylating a number of regulatory proteins such as ACAP1, POSH, Pak1, Girdin, etc. (Manning and Cantley 2007; Jiang and Liu 2009; Dillon and Muller 2010; Xue et al. 2012; Li et al. 2015). As a proto-oncoprotein, AKT can inhibit apoptosis by binding to Bcl-2-associated X protein (BAX) and hinder its ability to form openings in the mitochondrial outer membrane. Evidence reveals that in prostate cancer cells, activation of AKT corresponds to increased resistance to apoptosis (Patrucco et al. 2004; Guimaraes et al. 2015). Upon PIP3 formation, AKT and its upstream activating kinase, phosphoinositide-dependent kinase-1 (PDK-1), will translocate from the cytoplasm to the plasma membrane. The constitutively active PDK-1 will then induce the phosphorylation of AKT kinase domain at Thr308 and Ser473 in the carboxyl-terminal position to initiate the complete activation of AKT (Carpenter and Jiang 2013). AKT is capable of phosphorylating various substrates associated with cell metabolism, proliferation, survival, and motility (Liu et al., 2014). For example, AKT activity can positively regulate cell survival through activation of IkB kinase (IKK), a regulator of NfkB (Guimaraes et al. 2015). Mutations in its PH domain have been frequently found in cancers, which further supports the notion that AKT is an important effector for PI3K-associated oncogenic signaling (Fruman et al., 2017; Manning and Toker, 2017). AKT activation is also reversible as protein phosphatase 2A (PP2A) and pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP)
are capable of dephosphorylating pAKT and convert it back to inactive AKT (Wang 2013; Li and Wang 2014).
Mechanistic Target of Rapamycin (mTOR)

As an essential protein highly conserved through evolution, mechanistic target of rapamycin (mTOR) is known to regulate downstream signaling cascades by integrating both intra- and extra-cellular signals (Meng et al., 2018). Functions of mTOR are carried out by two cellular complexes, mTORC1 and mTORC2, each with its own distinct subunit composition and substrate selectivity (Saxton and Sabatini, 2017). mTORC1 consists of five components: mTOR, Raptor, mLST8, PRAS40, and DEPTOR (Hara et al., 2002; Meng et al., 2018; Kim et al., 2002; Kim et al., 2003; Peterson et al., 2009; Sancak et al., 2007; Vander Haar et al., 2007; Wang et al., 2007;). mTORC2 is composed of six components; mTOR, Rctor, mLST8, DEPTOR, mSin1, and Proctor 1/2 (Gaullier et al. 1998; Dou et al. 2013; Guimaraes et al. 2015; Meng et al., 2018; Jacinto et al., 2004; Sarbassoy et al., 2004; Kim et al., 2003; Peterson et al., 2009; Jacinto et al., 2006; Schroder et al., 2007; Yang et al., 2006; Pearce et al., 2007). As a key signaling node, mTORC1 regulates important cellular processes including autophagy, protein and lipid synthesis, and growth factor signaling (Jewell and Guan, 2013; Meng et al., 2018; Saxton and Sabatini, 2017). mTORC1 is able to stimulate protein synthesis and cell proliferation through the phosphorylation of S6 kinase-1 (S6K1) and 4EBP1, which elevates glycolysis and protein biosynthesis to initiate a “carcinogenic” metabolic reprogramming, and regulates translation initiation, respectively (Fruman et al., 2017; Dibble and Cantley, 2015; Ma and Blenis, 2009; Magnuson et al., 2012). On the other hand, mTORC2 is primarily responsible for cell survival, growth, proliferation, and cytoskeletal remodeling through phosphorylation of protein kinases A, G, and C family members (Ebner et al., 2017; Gan et al., 2012; Li and Gao 2014; Sarbassoy et al., 2004; Thomanetz et al., 2013).
The PI3K/AKT signaling pathway is known to stimulate mTORC activity by inactivating tuberous sclerosis complex (TSC) 1/2 phosphorylation (Carpenter and Jiang 2013; Manning et al., 2002; Rad et al., 2017). TSC consists of three components, TSC1, TSC2, and TBC1D7. The TSC complex primarily functions to inhibit the mTORC1 activator, Ras homolog enriched in the brain (Rheb) (Inoki et al., 2002; Manning et al., 2002).

Current studies suggest that mTOR is involved in a broad spectrum of functions including lipid generation, biosynthesis of nucleotide precursors, metabolic transformation, metastasis, etc. (Ben-Sahra et al., 2013; Rad et al., 2017; Valvezan et al., 2017; Yecies et al., 2011). Activated mTOR will also enhance the production of de novo proteins, mainly through increased number of ribosomes and accelerated protein translation (Iadevaia et al., 2014). In addition, mTOR can speed up G1 to S transition, which will drive more rapid cell proliferation and growth (Fingar et al., 2004). Examples of proteins regulated by mTOR include cyclin D1, HIF, and VEGF, which are required for the survival of many tumors (Mu et al. 1995; Stenmark et al. 1996; Guimaraes et al. 2015). mTOR/ribosomal protein S6 kinase beta-1 (p70S6K1) can also up-regulate AP-1 as well as other pro-angiogenic factors in promoting carcinogenic effects. Given the various cancerous characteristics promoted by mTOR activation, it is no surprising to find mTOR activation in approximately 70% of human cancers and this activation is often correlated with resistance to cancer therapy and overall poor survival rate for the patient (Forbes et al., 2011; Jiang & Liu, 2008; Rad et al., 2017).
**Arsenic and the PI3K/AKT/mTOR pathway**

The PI3K/AKT/ mTOR pathway has been regarded as a key regulator for many physiological processes including cell proliferation, growth, metabolism, and macromolecular synthesis (Li and Wang 2014; Guimaraes et al. 2015). Although PI3K/AKT and mTOR are two separate pathways, they are often considered as a single unique pathway due to functional interconnectedness. PI3K is evolutionarily conserved to respond to external growth signals. In mammals, activation of the pathway begins as a cellular response to various extracellular stimuli including epidermal growth factor receptor (EGFR), PDGF receptor (PDGFR), insulin-like growth factor receptor (IGFR), and insulin receptor (INSR) (Li and Wang 2014; Fruman et al., 2017). In consideration to its many important physiological roles, a homeostatically balanced PI3K/AKT/mTOR network is fundamental in maintaining normal cellular growth. On the other hand, aberrant activation of the signaling cascade will lead to considerable interruptions in cell proliferation, which can result in angiogenesis, metastatic competence, and potential therapy resistance (Porta et al., 2014). In other words, the PI3K/AKT/mTOR pathway exists as one of the most attractive targets for cancer development. Evidence suggests that chronic arsenic exposure-induced cell proliferation, migration, invasion, and anchorage-independent growth are strongly correlated with PI3K and AKT activation (Carpenter and Jiang 2013). A likely mechanism of arsenic-induced pathway activation is through stimulating upstream signals such as EGFR, which has been shown to induce aberrant epithelial cell proliferation (Gao et al. 2004; Hennessy et al. 2005; Jiang and Liu, 2008; Jiang and Liu 2009; Lee et al. 2010; Simeonova et al. 2002; Andrew et al. 2009; Wen et al. 2010; Carpenter and Jiang 2013). EGFR is a member of the ErbB family of receptor
tyrosine kinases and is commonly over-expressed in human malignancies such as cancers of the lung, breast, esophageal, etc, (Hirsch et al. 2003; Suzuki et al. 2005; Carpenter and Jiang 2013; Seshacharyulu et al., 2012). Conformational changes due to ligand-binding-induced EGFR dimerization allows for auto-phosphorylation at the C-terminal section of the receptor. Activated EGFR can interact with the p85 regulatory subunit of PI3K, which will stimulate the catalytic activity of p110 and initiate the activation of the PI3K/AKT pathway (Carpenter and Jiang 2013: 148-150). Subsequently, AKT can indirectly inhibit TSC2, thereby activate mTOR signaling (Carnero, 2010; Jiang and Carpenter, 2013). In fact, studies have shown that cells treated with arsenic along with PI3K inhibitor LY294002 will result in reduced p70S6K phosphorylation and subsequent mTOR activation, indicating that mTOR activity is regulated by upstream PI3K activation (Altman et al. 2007; Wang and Proud 1997; Jung et al 2003; Skinner et al. 2004; Castorina et al. 2008; Lee et al. 2010; Carpenter et al. 2011; Wu et al. 2011; Carpenter and Jiang 2013; Yoon et al. 2006). EGFR and activated PI3K/AKT, and mTOR pathways have all been shown to stimulate cell transformation and angiogenesis, see Figure 1. Effectors of the signaling cascade include HIF-1, AP-1, FOXO, NF-kB, which are important factors in promoting cancer formation (Carpenter and Jiang 2013; Hu et al. 2005; Xia et al. 2006; Fang et al. 2007; Jiang and Liu 2009).
Arsenic can differentially regulate PI3K/AKT/mTOR in different cell types

Cancer promoting

As a potent human carcinogen, chronic arsenic exposure has been long been known to induce cancers of the lung. In multiple studies, human bronchial epithelial (BEAS-2B) cells illustrated activated AKT and mTOR activity after arsenic exposure (Carpenter et al., 2011; Liu et al., 2012; Beezhold et al., 2011; Zhang et al., 2006). Despite high variability in dosage (0-20uM), type of compound (NaAsO₂, AsCl₃), and length of exposure (4 hours to 26 weeks), all of the treatment conditions resulted in increased pathway activity when compared to the control groups, see Table 1. Along with activated AKT and mTOR activity, arsenic-exposed cells also demonstrated higher rate of proliferation, survival, and anchorage-independent growth, all of which are unique hallmarks of malignant cell transformation. Similar results were also found in primary human bronchial epithelial (HBEC) cells (Wang et al., 2012). In addition to bronchial epithelial cells, mouse epidermis-derived JB6 Cl41, as well as normal human bladder SV-HUC-1 and A375 cells all demonstrated activated PI3K and AKT activity after arsenic exposure (Ouyang et al., 2005; Li et al., 2015; Wang et al., 2013). In vivo experiment treating Wistar rats and C57BL/6 mice with 1.0 umol/L of roxarsone revealed activated PI3K and AKT phosphorylation in the vascular endothelial cells (Wang et al., 2016). In fact, both acute and chronic arsenic treatments have been found to promote PI3K/AKT phosphorylation. In one study, after treating SV-HUC-1 cells with 1uM of arsenic trioxide for eight to 10 months, results from western blotting analysis showed significant elevation in the expression of mTOR protein as well as phosphorylation of PI3K and AKT (Michailidi et al. 2015).
Cancer suppressing

While evidence suggests arsenic is capable of activating the PI3K/AKT/mTOR pathway and stimulating cell proliferation in normal cells such as BEAS2B and SV-HUC-1, the opposite phenomenon seems to occur in cancerous cells. Specifically, arsenic induces apoptosis to varying degrees in different types of cancer cells such as HT-29 colon, neuroblastoma, prostate, B-cell leukemic, and gastrointestinal cancer cells (Akao et al. 1999; Cha et al. 2006; Ma et al. 2014; You et al. 2015; Stevens et al. 2016). In most of these studies, arsenic trioxide is used instead of sodium arsenite or arsenic trichloride, which are typically used for treatment of non-carcinoma cell studies, see Tables 1 and 2. Arsenic trioxide has been used as a key ingredient in traditional Chinese medicine for over 5000 years (Au 2011). Over time, the demand and appeal for arsenic diminished due to its intrinsic toxicity. Nevertheless, in the 1970s, researchers from China discovered the therapeutic effects of arsenic trioxide against acute promeylocytic leukemia, and the FDA later approved its usage in 2000 (Antman 2001). Today, arsenic trioxide is still being used as an effective drug against acute promyelocytic leukemia, mainly through inducing cancer cell death (Baysan et al. 2007; Li and Wang, 2014). However, tolerable doses of arsenic trioxide has been found to be most effective in inducing apoptosis in acute APL, but not as effective in other malignant cells (Koren et al. 2008). Furthermore, arsenic may preferentially target cancer cells rather than normal cells. For instance, arsenic trioxide (ATO) has been found to limit PI3K/AKT induced cellular proliferation and increase the amount of apoptosis in B-CLL cells, but not in normal peripheral blood lymphocytes (Redondo-Muñoz et al. 2010).
In both human Burkitt’s lymphoma and human leukemia cell lines, high exposure to arsenic trioxide, above 5µM for over 24 hrs, has been shown to induce cell apoptosis (Chen et al. 1996; Baysan et al. 2007; Li and Broome 1999; Choi et al. 2012; Li and Wang 2014). A likely explanation for this phenomenon is the induction of reactive oxygen species through arsenic toxicity, which in turn decreases AKT activity and promote pro-apoptotic features. In human gastric cancer (SGC-7901) cell lines, arsenic trioxide exposure for up to 72 hrs led to decreased phosphorylation at two AKT sites, Ser 473 and Thr308, although the protein levels stayed relatively same, indicating that arsenic is capable of reducing activation of AKT rather than the total protein (Gao et al. 2014). In another study led by Wang et al. 2017, As$_2$S$_2$ has been found to inhibit the AKT/mTOR signaling pathway and induce autophagy and apoptosis in several osteosarcoma cell lines. Specifically, human osteosarcoma 143B, MG-63, U-2OS, and HOS cells were subjected to either 24h or 48hr treatment. Dosages of arsenic ranged from 3.02µM to 13.06µM. Western blotting data suggests that As$_2$S$_2$ led to a reduction in both the protein amount as well as activity/phosphorylation of mTOR and AKT (Wang et al. 2017). In a separate study based on chondrosarcoma cells, researchers were able to find similar therapeutic benefits of arsenic in suppressing cancer cell growth (Jiao et al. 2015). Human chondrosarcoma cells, HCS-2/8, OUMS-27, and SW1353, were subject to 12, 24, or 48hr of arsenic trioxide exposure, concentrations ranging from 1-20µM. MTT assays after the treatment illustrated decreased cell viability and high levels of apoptosis. Western blot analyses demonstrated a dose-dependent decrease in AKT and mTOR phosphorylation due to arsenic exposure, which led the researchers to conclude that arsenic trioxide may induce apoptosis via inhibition of the AKT/mTOR pathway.
On the other hand, ATO may not always be effective when acting alone. In one study, HL60 cells were treated with both ATO and 2-Deoxy-D-Glucose, an anti-glycotic drug, resulting in dephosphorylated AKT. However, ATO alone lead to insignificant changes to the phosphorylation levels (Estan et al., 2012). Similarly, Lonidamine, an anti-tumor drug, has also been shown to inactivate PI3K/AKT when used in combination with ATO (Calvino et al., 2011). In addition, dosage and length of ATO exposure also seems to control the PI3K/AKT pathway. In a study using both NB4 and gastric cancer cells, after the initial 4 hour ATO treatment, AKT phosphorylation heightened. But after decreased again after 16-24hrs of treatment (Li et al., 2009). The controversial biological effect of arsenic, hence its biphasic effect on carcinogenesis, may depend on the type of compound and strength of exposure (Wang et al., 2016).

**Challenges in targeting PI3K/AKT/mTOR pathway for cancer therapy**

In consideration to the many important roles in multiple physiological functions, cell growth and metabolism, the PI3K/AKT and mTOR pathways are crucial targets for cancer therapy. However, efforts using target inhibitors have proven to be inefficient mainly due to three reasons. First, activation of the pathways can be initiated by various receptors due to cancer cells’ high plasticity in amplifying the upstream targets to stimulate compensatory pathways and maintaining persistent signal flow (Fruman et al., 2017). Second, persistent administration of the inhibitors can induce resistance due to mutations of regulatory genes responsible for the pathways. In fact, the PI3K and mTOR pathways are important targets for resistance to cancer immunotherapy (Fruman et al., 2017). Third, studies suggest that significant reductions in PI3K and AKT phosphorylation is needed to generate optimal therapeutic outcome in most cancer
patients (Fruman et al., 2017). For instance, in order to induce hyperglycemic response in mice, inhibition of hepatic PI3K/AKT signaling needs to reach more than 90% efficiency (Fruman et al., 2017; Taniguchi et al., 2006). However, inhibitors with the greatest potentials for effective therapeutic activity, such as pan-pI3K and pan-specific PI3K/mTOR inhibitors, also exert high toxicity burdens. So while high doses may be effective in targeting tumor tissues, the resulting adverse effects such as hyperglycaemia and liver damage releasing transaminases, are limiting factors for administrating most effective dosages.
Discussion

More than 200 million people around the world are exposed to arsenic at levels above the maximum contaminant level of 10 ppb, either through drinking water, inhalation, and or diet. As a class I human carcinogen, exposure to arsenic has been documented to cause neurodevelopmental deficits, cardiovascular disease, various human cancers including that of the lung, bladder, kidney, liver etc. Various mechanisms of arsenic-induced carcinogenesis have been proposed, and this review specifically focused on the PI3K/AKT/mTOR pathway in an effort to better understand arsenic’s ability to induce the intrinsic characteristics of cancer development: cell proliferation and anti-apoptosis. As a critical pathway for a multitude of biological and physiological functions such as cell survival, proliferation, apoptosis, and metabolism. Multiple studies have demonstrated a link between arsenic and the activity of the PI3K/AKT/mTOR pathway in stimulating malignant cell transformation through uncontrolled cell proliferation. In addition, it is interesting to note that mTOR acts as a major negative regulator of autophagy, a process in which old and damaged cells are degraded (Heras-Sandoval et al., 2014). The activation of PI3K/AKT/mTOR signaling pathway not only stimulates growth, but can also halt autophagy, which may promote the extended survival of damaged cells and subsequent replication. In fact, previous studies have illustrated that arsenic is capable of inducing prolonged activation of Nrf2 through autophagic dysfunction as a way of promoting cancer development (Lau et al., 2013). The link between arsenic and PI3K/AKT/mTOR pathway-induced autophagy may be an interesting area for future studies. On the other hand, arsenic trioxide has been successfully used to treat acute promyelocytic leukemia through inducing cell death in the cancer cells. The specificity of
this successful treatment is likely due to the narrow mutations of specific pro-apoptotic proteins that drive PML. Current studies suggest that arsenic can manipulate the PI3K/AKT/mTOR pathway to induce cell proliferation as well as apoptosis, two conflicting mechanisms. The ability for arsenic to achieve opposite cellular responses may be related to the exposure conditions (dose and time) as well as the type of cells used. It is imperative for future studies to establish and pinpoint the exact conditions for arsenic to differentially regulate the PI3K/AKT/mTOR pathway in order to maximize the therapeutic and minimize the carcinogenic effects of arsenic.

Author Contributions

Both authors contributed equally to this work.
References

Altman J, Yoon P, Katsoulidis E, Kroczyńska B, Sassano A, Redig A, Glaser H, Jordan A, Tallman MS, Hay N, and Platanias LC (2007) Regulatory target of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. *JBC* 283: 1992-2001.

Akao Y, Nakagawa Y, and Akiyama K (1999) Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. *FEBS Letters* 455:59-62.

Andrew A, Mason R, Memoli V, and Duell E (2009) Arsenic activates EGFR pathway signaling in the lung. *Toxicol. Sci* 109: 350-357.

Antman K (2001) Introduction: the history of arsenic trioxide in cancer therapy. *Oncologist* 6.

Au W (2011) A biography of arsenic and medicine in Hong Kong and China. *Hong Kong Med J* 17:507-13.

Axelson O, Dahlgren E, Jansson C, and Rehnlund S (1978) Arsenic exposure and mortality: a case-referent study from a Swedish copper smelter. *Br. J. Ind. Med* 35:8-15.

Barchowsky A, Dudek E, Treadwell M, and Wetterhahn K (1996) Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. *Free Radic Biol Med* 21:783-790.

Bartholomeusz C, and Gonzalez-Angulo A (2012) Targeting the PI3K signaling pathway in cancer therapy. *Expert Opinion on Therapeutic Targets* 16:121-30.
Baysan A, Yel L, Gollapudi S, Su H, and Gupta S (2007) Arsenic trioxide induces apoptosis via the mitochondrial pathway by upregulating the expression of Bax and Bim in human B cells. *Int. J. Oncol* 30:313–318.

Beezhold K, Liu J, Kan H, Meighan T, Castranova V, Shi X, and Chen F (2011). miR-190-mediated downregulation of PHLPP contributes to arsenic-induced Akt activation and carcinogenesis. *Toxicol. Sci* 123:411–420.

Ben-Sahra I, Howell J, Asara J, and Manning B (2013) Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. *Science* 339:1323-1328.

Calvino E, Estan M, Simon G, Sancho P, Bovano-Adanez Mdel C, de Blas E, Breard J, and Aller P (2011) Increased apoptotic efficacy of ionidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK,Akt/mTOR) modulation. *Biochem Pharmacol* 1:1619-1629.

Carnero, A (2010) The PKB/AKT pathway in cancer. *Curr. Pharm. Des* 16:34-44.

Carpenter R, and Jiang B (2013) Roles of EGFR, PI3K, AKT, mTOR in heavy metal-induced cancer. *Current cancer drug targets* 13:252-266.

Carpenter R, Jiang Y, Jing Y, He J, Rojanasakul Y, and Liu L (2011) Arsenite induces cell transformation by reactive oxygen species, AKT, ERK1/2, and p70S6K1. *Biochemical and biophysical research comm* 414:533-538.

Castorina A, Tiralongo A, Cavallo D, Loreto C, Carnazza M, Iavicoli S, D’Agata V (2008) Expression profile of ERBB receptor's family in human alveolar type 2-
like cell line A549 exposed to hexavalent chromium. *Toxicol. In Vitro* 22: 541-547.

Cha Y, Park D-W, Lee C, Baek S, Kim S, Kim J, Kim J (2006) Arsenic Trioxide Induces Apoptosis in Human Colorectal Adenocarcinoma HT-29 Cells Through ROS. *Cancer Research and Treatment: Official Journal of Korean Cancer Association* 38:54-60.

Chen G, Zhu J, Shi X, Ni J, Zhong H, Si G, Jin X, Tang W, Li X, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, and Chen Z (1996) In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. *Blood* 88:1052–1061.

Chen Q, and Costa M (2017). Epigenetic phenomena of arsenic and histone tail modifications: implications for diet and nutrition. In: Handbook of Nutrition, Diet, and Epigenetics. *Springer, Cham*.

Choi Y, Park J, Suh S, Mun K, Bae J, Song D, Ki SP, Kwon TK (2002) Arsenic trioxide-induced apoptosis in U937 cells involve generation of reactive oxygen species and inhibition of Akt. *Int. J. Oncol.* 21:603–610.

Czech M (2000) PIP2 and PIP3 Complex Roles at the Cell Surface. *Cell* 100:603-606.

Dibble C, and Cantley L (2015) Regulation of mTORC1 by PI3K signaling. *Trends Cell Biol* 25:545-555.

Dillon R and Muller W (2010) Distinct biological roles for the akt family in mammary tumor progression. *Cancer Res* 70:4260-4264.
Dou Z, Pan J, Dbouk H, Ballou L, DeLeon J, Fan Y, Chen JS, Liang Z, Li G, Backer JM, Lin RZ, Zong WX (2013) Class IA PI3K p110b subunit promotes autophagy through Rab5 small GTPase in response to growth factor limitation. *Molecular Cell* 50: 29-42.

Ebner M, Sinkovics B, Szczygiel M, Ribeiro D, and Yudushkin L (2017) Localization of mTORC2 activity inside cells. *J. Cell Biol* 216:343-353.

Enterline P, Henderson V, and Marsh G (1987) Exposure to arsenic and respiratory cancer. A reanalysis. *Am. J. Epidemiol* 125: 929-938.

Estan M, Calvino E, de Blas E, Bovano-Adanez Mdel C, Mena M, Gomez-Gomez M, Rial E, Aller P (2012) 2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways. *Biochem Pharmacol* 15:1604-1616.

Fang J, Ding M, Yang L, Liu L, and Jiang B (2007) PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. *Cell Signal* 19:2487-2497.

Fingar D, Richardson C, Tee A, Cheatham L, Tsou C, and Blenis J (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. *Mol. Cell. Biol* 24:200-216.

Forbes S, Bindal N, Bamford S, Cole C, Kok C, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague J, Campbell P, Stratton M, and Futreal A (2011) COSMIC: Mining complete cancer genomes in the Catalogue of somatic mutations in cancer. *Nucleic Acids Res* 39:D945-D950.
Fresno V, Casado E, de Castro J, Ceias P, Belda-Iniesta C, and Gonzalez-Baron (2004) PI3K/Akt signaling pathway and cancer. *Cancer Treat Rev* 30:193-204.

Fruman D, Chiu H, Hopkins B, Bagrodia S, Cantley L, and Abraham R (2017) The PI3K pathway in human disease. *Cell* 170:605-635

Gan X, Wang J, Wang C, Sommer E, Kozasa T, Srinivasula, S, Alessi D, Offermanns S, Simon M, Wu D (2012) PRR5L degradation opromotes mTORC2-mediated PKC-delta phosphorylation and cell migration downstream of Galpha 12. *Nat cell biol* 14:686-696.

Gao N, Ding M, Zheng J, Zhang Z, Leonard S, Liu K, Shi X, and Jiang B (2002) Vanadate-induced expression of hypoxia-inducible factor 1α and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. *J. Biol. Chem* 277:31963–31971.

Gao N, Shen L, Zhang Z, Leonard S, He H, Zhang X, Shi X, and Jiang B (2004) Arsenite induces HIF-1α and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. *Mol. Cell. Biochem* 255:33–45.

Gao Y, Zhang H, Yang S, Yang Y, Ma Y, Zhang X, Yang Y (2014) Inactivation of AKT by arsenic trioxide induces cell death via mitochondrial-mediated apoptotic signaling in SGC-7901 human gastric cancer cells. *Oncology reports* 31: 1021-335X.

Gaullier J, Simonsen A, D’Arrigo A, Bremnes B, Stenmark H, and Aasland R (1998) FYVE fingers bind PtdIns(3)P. *Nature* 394:432-433.
Guimaraes I, Tessarollo N, Lyra-Junior P, Santos D, Zampier R, de Oliveira L, Sigueira K, Silva I, and Rangel L (2015) Targeting the PI3K/AKT/mTOR Pathway in Cancer Cells. *InTechOpen*.

Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Ayruch J, and Yonezawa K (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. *Cell* 110:177-189.

Hennessy B, Smith D, Ram P, Lu Y, and Mills G (2005) Exploiting the PI3K/AKT pathway for cancer drug discover. *Nat. Rev. Drug Discov* 4:988-1004.

Heras-Sandoval D, Perez-Rojas J, Hernandez-Damian J, and Padreza-Cheverri J (2014) The role of PI3K/AKT/mTOR in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cellular signaling 26(12):2694-2701.

Hirsch F, Varella-Garcia M, Bunn P, Di Maria M, Veve R, Bremmes R, Baron Ae, Zeng C, Franklin WA (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. *J. Clin. Oncol* 21: 3798-3807.

Hu L, Hofmann J, & Jaffe R. Phosphatidylinositol 3-kinase mediates angiogenesiss and vascular permeability associated with ovaryan carcinoma. *Clin. Cancer Res* 2005, 11:8208-8212.

Huang C, Ke Q, Costa M, and Shi X (2004) Molecular mechanisms of arsenic carcinogenesis. *Mole Cell Biochem* 255:57.

Huang C, Ma W, Li J, Goranson A, and Dong Z (1999) Requirement of Erk, but not JNK, for arsenite-induced cell transformation. *J Biol Chem* 274: 14595–14601.
Iadevaia V, Liu R, and Proud C (2014) mTORC1 signaling controls multiple steps in ribosome biogenesis. *Semin Cell Dev. Biol* 36:113-120.

Inoki K, Li Y, Zhu T, Wu J, and Guan K (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. *Nat. Cell Biol* 4:648-657.

Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg M, Hall A, Hall MN (2004) mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. *Nat. Cell Biol* 6:1120-1128.

Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung S, Huang Q, Qin J, Su B (2006) SIN1/MIP1 maintainas Rictor-mTOR complex integrity and regulates AKT phosphorylation and substrate specificity. *Cell* 127:125-137.

Jewell J and Guan K (2003) Nutrient signaling to mTOR and cell growth. *Trends Biochem. Sci* 38:233-242.

Jiang B and Liu L (2009) PI3K/PTEN signaling in angiogenesis and tumorigenesis. *Adv. Cancer Res* 102:19-65.

Jiang B, and Liu L (2008) Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment. *Drug Resist. Updat* 11:63-76.

Jiao G, Ren T, Guo W, Ren C, and Yang K (2015) Arsenic trioxide inhibits growth of human chondrosarcoma cells through G2/M arrest and apoptosis as well as autophagy. *Tumor Biol* 36:3969-3977.

Jing Y, Liu L.Z, Jiang Y, Zhu Y, Guo N, Barnett J, Roianasakul Y, Agani F, Jiang B (2012) Cadmium increases HIF-1 and VEGF expression through ROS, ERK, and AKT signaling pathways and induces malignant transformation of human bronchial epithelial cells. *Toxicol. Sci* 125:10–19.
Jung D, Bae G, Kim Y, Han S, Choi W, Kang H, Seo DW, Lee HY, Cho EJ, Lee HW, and Han JW (2003) Hydrogen peroxide mediates arsenite activation of p70(s6k) and extracellular signal-regulated kinase. *Exp. Cell Res* 290: 144-154.

Kandoth C, McLellan M, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael J, Wyczalkowski M, Leiserson M, Miller C, Welch J, Walter M, Wndl M, Ley T, Wilson R, Raphael B, and Ding Li (2013) Mutational land- scape and significance across 12 major cancer types. *Nature* 502:333-339.

Kim D, Sarbassoy D, Ali S, King J, Latek R, ErdjumentBromage H, Tempst P, Sabatini DM (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. *Cell* 110:163-175.

Kim D, Sarbassoy D, Ali S, Latek R, Guntur K, ErdjumentBromage H, Tempst P, Sabatini DM (2003) GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. *Mol. Cell* 11:895-905.

Koren M, Myrian C, and Wilson M (2008) Arsenic trioxide decreases AKT protein in a caspase-dependent manner. *Molecular cancer therapeutics* 10.1158/1535-7163.MCT-07-2164.

Lander H (1997) An essentiall role of free radicals and derived species in signal transduction. *Faseb J* 11:118-124.

Lau A, Zheng Y, Tao S, Wang H, Whitman S, White E, and Zhang D (2013) Arsenic inhibits autophagic flux, activating nrf2-keap1 pathway in a p62-dependent manner. *Mole Cell Biol* 33(12):2436-2446.
Lawrence M, Stojanov P, Mermel C, Robinson J, Garraway L, Golub T, Meyerson M, Gabriel S, Lander E, and Getz G (2014) Discovery and saturation analysis of cancer genes across 21 tumor types. *Nature* 505:495-501

Levine B (2007) Cell biology: autophagy and cancer. *Nature* 446:745-7.

Lee K, Hwang M, Lee D, Lee K, and Lee H (2010) Protective effect of quercetin against arsenite-induced COX-2 expression by targeting PI3K in rat liver epithelial cells. *J. Agric. Food Chem* 58: 5815-5820.

Li J, Oberley L, Fan M, and Colburn N (1998) Inhibition of AP-1 and NIF-kappB by manganese-containing superoxide dismutase in human breast cancer cells. *Faseb J* 12:1713-1723.

Li L, Lu Y, Stemmer P, and Chen F (2015) Filamin A phosphorylation by akt promotes cell migration in response to arsenic. *Oncotarget* 6:12009-12019.

Li T, and Wang G (2014) Computer-Aided Targeting of the PI3K/Akt/mTOR Pathway: Toxicity Reduction and Therapeutic Opportunities. Johnson D, ed. *International Journal of Molecular Sciences* 15:18856-18891.

Li Y, and Broome J (199) Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. *Cancer Res* 59:776–780.

Li Y, Qu X, Qu J, Zhang Y, Liu J, Teng Y, Hu X, Hou K, and Liu Y (2009) Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation. *Cancer Lett* 1:208-215.

Liu F, and Jan K (2000) DNA damage in arsenite-and cadmium-treated bovine aortic endothelial cells. *Free Radic Biol Med* 28: 55–63.
Liu L, Jiang Y, Carpenter R, Jing, Peiper S, and Jiang B (2011) Role and mechanism of arsenic in regulating angiogenesis. *PLoS. One* 6: e20858.

Liu P, Begley M, Michowski W, Inuzuka H, Ginzberg M, Gao D, Tsou P, Gan W, Papa A, Kim B, Wan L, Singh A, Zhai B, Yuan M, Wang Z, Gygi S, Lee T, Lu K, Toker A, Pandolfi P, Asara J, Kiirschner M, Sicinski P, Cantley L, and Wei W (2014) Cell-cycle-regualted activation of Akt kinase by phosphorylation at its carboxyl terminus. *Nature* 408:541-545.

Lynn S, Gurr J, Lai H, and Jan K (2000) NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. *Circ Res* 86: 514–519

Ma X, and Blenis J (2009) Molecular mechanisms of mTOR-mediated translational control. *Nat. Rev. Mol. Cell Biol* 10:307-318.

Ma Z, Xu H, Jiang M, Yang Y, Liu L, and Li Y-H (2014) Arsenic trioxide induces apoptosis of human gastrointestinal cancer cells. *World Journal of Gastroenterology : WJG* 20:5505-5510.

Magnuson B, Ekim B, and Fingar D (2012) Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signaling networks. *Biochem J* 441:1-21.

Manning B, and Cantley L (2007) AKT/PKB signaling: navigating downstream. *Cell* 129:1261–1274.

Manning B, Tee A, Logsdon M, Blenis J, and Cantley L (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. *Mol. Cell* 10:151-162.
Manning B, and Toker A (2017) AKT/PKB signaling: navigating the network. *Cell* 169:381-405.

Meng D, Frank A, and Jewell J (2018) mTOR signaling in stem and progenitor cells. *Development* 145.

Michailidi C, Hayashi M, Datta S, Sen T, Zenner K, Oladeru O, Brait M, Izumchenko E, Baras A, VandenBussche C, Argos M, Bivalacqua TJ, Ahsan H, Hahn NM, Netto GJ, Sidransky D, Hogue MO (2015) Involvement of epigenetics and EMT related miRNA in arsenic induced neoplastic transformation and their potential clinical use. *Cancer prevention research (Philadelphia, Pa)* 8:208-221.

Moon K, Guallar E, and Navas-Acien A (2012) Arsenic exposure and cardiovascular disease: an updated systematic review. *Curr. Atheroscler. Rep* 14: 542–555.

Mu F, Callaghan J, Steele-Mortimer O, Stenmark H, Parton R.G, Campbell P.L, McCluskey J, Yeo JP, Tock EP, and Toh BH (1995) EEA1, an early endosome-associated protein. EEA1 is a conserved alpha- helical peripheral membrane protein flanked by cysteine “fingers” and contains a calmodulin-binding IQ motif. *Journal of Biological Chemistry* 270:13503– 13511.

Naujokas M, Anderson B, Ahsan H, Aposhian H, Graziano J, Thompson C, Suk WA (2013) The broad scope of health effects from chronic arsenic exposure: update on worldwide public health problem. *Environ Health Perspect* 121:295-302

Ouyang W, Li J, Ma Q, and Huang C (2005) Essential roles of PI-3K/Akt/IKKβ/NFκB pathway in cyclin D1 induction by arsenite in JB6 Cl41 cells. *Carcinogenesis* 27:864–873.
Patrucco E, Notte A, Barberis L, Selvetella G, Maffei A, Brancaccio M, Marengo S, Russo G, Azzolino O, Rybalkin SD, Silengo L, Alturda F, Wetzker R, Wymann MP, Lembo G, Hirsch E, (2004) PI3K gamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and –independent effects. *Cell* 118:375-387.

Pearce L, Huang X, Boudeau J, Pawlowski R, Wullschleger S, and Deak M (2007) Identification of Protor as a novel Rictor-binding component of mTOR complex-2. *Biochem. J* 405:513-522.

Peterson T, Laplante M, Thoreen C, Sancak Y, Kang S, Kuehl W, Gray NS, Sabatini DM (2009) DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. *Cell* 137:873-886.

Porta C, Paglino C, and Mosca A (2014) Targeting PI3K/Akt/mTOR signaling in cancer. *Front Oncol* 4:64.

Rad E, Murray J, and Tee A (2018) Oncogenic signaling through mechanistic target of rapamycin (mTOR): A driver of metabolic transformation and cancer progression. *Cancers* 10:5.

Rameh L, and Cantley L (1999) The role of phosphoinosidite 3-kinase lipid products in cell function. *J. Biol. Chem* 274:8347-8350.

Rauch J, Kolch W, and Mahmoudi M (2012) Cell type-specific activation of AKT and ERK signaling pathways by small negatively-charged magnetic nanoparticles. *Sci. Rep* 2.

Redondo-Muñoz J, Escobar-Díaz E, Hernández del Cerro M, Pandiella A, Terol M, García-Marcoand J, Garcia-Pardo A (2010) Induction of B-Crronic
lymphocyteic leukemia cell lapoptosis by arsenic trioxide involves suppression of the phosphorinositide 3-kinase/akt survival pathway via c-jun-NH2 terminal kinase activation and pten upregulation. Clinical cancer research 16:4382-91.

Rossman T, Stone D, Molina M, and Troll W (1980) Absence of arsnite mutagenicity in E. coli and Chinese hamster cells. Environ Mutagen 2:371-379.

Roy R, Singh S, Chauhan K, Das M, Tripathi A, and Dwivedi P (2014) Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition. Toxicol. Lett 227:29–40.

Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo H, Yan H, Gazdar A, Powell SM, Riggins GJ, Wilson JK, Markowitz S, Kinzler KW, Bogelstein B, Velculescu VE (2004) High frequency of mutations of the PI3KCA gene in human cancers. Science 304:554

Sancak Y, Thoreen C, Peterson T, Lindquist R, Kang S, Spooner E, Carr SA, Sabatini DM (2007) PRAS40 is an insulinregulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25:903-915.

Sarbassov D, Ali S, Kim D, Guertin D, Latek R, ErdjumentBromage H, Tempst P, Sabatini DM (2004) Rictor a novel binding partner of mTOR, defines a rapamycin-insensitive and Raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14:1296-1302.

Saxton R, and Sabatini D (2017) mTOR signaling in growth, metabolism, and disease. Cell 168:960-976.
Schroder W, Buck M, Cloonan N, Hancock J, Suhrbier A, Sculley T, Bushell G (2007) Human Sin1 contains Ras-binding and pleckstrin homology domains and suppresses Ras signaling. *Cell Signal* 19:1279-1289.

Sen C and Packer L (1996) Antioxidant and redox regulation of gene transcription. *Faseb J* 10:709-720.

Seshacharyulu P, Moorthy P, Dhanya H, Maneesh J, Apark G, and Surinder B (2012) Targeting the EGFR signaling pathway in cancer therapy. *Expert Opin Ther Targets* 16:15-31.

Shankar S, Shankaer U, and Shikha (2014) Arsenic contamination of groundwater: A review of sources, prevalence, health risks, and strategies for mitigation. *The scientific world journal.* 2014; 1-18. doi:10.1155/2014/304524

Skinner H, Zhong X, Gao N, Shi X, and Jiang B (2004) Arsenite induces p70S6K1 activation and HIF-1alpha expression in prostate cancer cells. *Mol. Cell Biochem* 255: 19-23.

Simeonova P, Wang S, Hulderman T, and Luster M (2002) c-Srcdependent activation of the epidermal growth factor receptor and mitogen-activated protein kinase pathway by arsenic. Role in carcinogenesis. *J. Biol. Chem* 277: 2945-2950.

Snow E (1992) Metal carcinogenesis: Mechanistic implications. *Pharmacol Ther* 53: 31–65

Stenmark H, Aasland R, Toh B.H, and D’Arrigo A (1996) Endosomal localization of the auto- antigen EEA1 is mediated by a zinc-binding FYVE finger. *Journal of Biological Chemistry* 271:24048–24054.
Stevens J, Graham B, Dugo E, Berhaneselassie-Sumner B, Ndebele K, and Tchounwou P (2016) Arsenic Trioxide Induces Apoptosis via Specific Signaling Pathways in HT-29 Colon Cancer Cells. *J Cancer Sci Ther* 9:298-306.

Suzuki S, Dobashi Y, Sakurai H, Nishikawa K, Hanawa M, and Ooi A (2005) Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. *Cancer* 103:1265-1273.

Tai S, Xu L, Xu M, Zhang L, Zhang Y, Zhang K, Liang C (2017) Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells. *Oncotarget* 8:11206-11218.

Taniguchi C, Kondo T, Sajan M, Luo J, Bronson R, Asano T, Earese R, Cantley LC, Kahn Cr (2006) Divergent regulation of hepatic glucose and lipid metabolism by phosphoinosidite 3-kinase via Akt and PKClamda/zeta. *Cell Metab* 3:343-353.

Thomanetz V, Angliker N, Cloetta D, Lustenberger R, Schweighauser M, Oliveri F, Suzuki N, Ruegg MA (2013) Ablation of the mTORC2 component Rictor in brain or Purkinje cells affects size and neuron morphology. *J. Cell Biol* 201:293-308.

Valvezan A, Turner M, Belaid A, Lam H, Miller S, McNamara M, Baglini C, Housden BE, Perrimon N, Kwiatkowski DJ, Asara JM, Henske EP, Manning BD (2017) mTORC1 couples nucleotide synthesis to nucleotide demand resulting in a targetable metabolic vulnerability. *Cancer Cell* 32:624-638.

Vander H, Lee S, Bandhakavi S, Griffith T, and Kim D (2007) Insulin-singaling to mTOR mediated by the Akt/PKB substrate PRAS40. *Nat. Cell Biol* 9:316-323.
Wang C, Mayo M, and Baldwin A (1996) TNF-and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB. *Science* 274: 784–787.

Wang G (2013) Analysis of Complex Diseases: A Mathematical Perspective. CRC Press; Boca Raton, FL, USA.

Wang G, Zhang T, Sun W, Wang H, Yin F Wang Z, Zuo D, Sun M, Zhou Z, Lin B, Xu J, Hua Y, Li H, Cai Z (2017) Arsenic sulfide induces apoptosis and autophagy through the activation of ROS/JNK and suppression of Akt/mTOR signaling pathways in osteosarcoma. *Free Radical Biol. And Medi.* 2017, 123:411-420.

Wang L, Jiang H, Yin Z, Aschner M, and Cai J (2009) Methylmercury toxicity and Nrf2-dependent detoxification in astrocytes. *Toxicol. Sci.* 107:135–143.

Wang Y, Yin D, Xu C, Wang K, Zheng L, and Zhang Y (2016) Roxarsone induces angiogenesis via PI3K/Akt signaling. *Cell Biosci* 6:54.

Wang X and Proud C (1997) G. p70 S6 kinase is activated by sodium arsenite in adult rat cardiomyocytes: roles for phosphatidylinositol 3-kinase and p38 MAP kinase. *Biochem. Biophys. Res. Commun* 238: 207-212.

Wang Z, Yang J, Fisher T, Xiao H, Jiang, and Yang C (2012) Akt activation is response for enhanced migratory and invasive behaveor of arsenic-transformed human brochial epithelial cells. *Environmental health perspectives* 120:92-97.

Wen G, Hong M, Calaf G, Roy D, Patridge M, Li B, Hei TK (2010 Phosphoproteomic profiling of arsenite-treated human small airway epithelial cells. *Oncol. Rep* 23: 405-412.

West K, Brognard J, Clark A, Linnoila I, Yang X, Swain S, Harris Curtis, Belinsky S, and Dennis P (2003) Rapid Akt activation by nicotine and a tobacco carcinogen
modulates the phenotype of normal human airway epithelial cells. *J. Clin. Investig* 111:81–90.

Wu X, Wang X, Wu S, Lu J, Zheng M, Wang Y, Zhou H, Zhang H, Han J (2011) Phosphorylation of Raptor by p38beta participates in arsenite-induced mammalian target of rapamycin complex 1 (mTORC1) activation. *J. Biol. Chem* 286: 31501-31511.

Xia C, Meng Q, Cao Z, Shi X, and Jiang B (2006) Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression. *J. Cell Physiol* 209:56-66.

Xue G, Restuccia D, Lan Q, Hynx D, Dirnhofer S, Hess D, Rueggs C, Hemmings BA (2012) Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-beta signaling axes. Cancer Discov 2:248–259.

Xue P, Hou Y, Zhang Q, Woods C, Yarborough K, Liu H, Sun G, Anderson ME, Pi J (2011) Prolonged inorganic arsenite exposure suppresses insulin-stimulated AKT S473 phosphorylation and glucose uptake in 3T3-L1 adipocytes: Involvement of the adaptive antioxidant response. *Biochemical and Biophysical Research Communications* 407: 360–365.

Yang Q, Inoki K, Ikenoue T, and Guan K (2006) Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. *Genes Dev* 20:2820-2332.

Yecies J, Zhang H, Menon S, Liu S, Yecies D, Lipoysky A, Gorgun C, Kwiatkowski DJ, Hotamisligil GS, Lee CH, Manning BD (2011) Akt stimulates hepatic SREBP1c
and lipogenesis through parallel mTORC1-dependent and independent pathways. *Cell Metab* 14:21-32.

Yoon P, Giafis N, Smith J, Mears H, Katsoulidis E, Sassano A, Altman J, Redig AJ, Tallman MS, Platanias LC (2006) Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. *Research Articles: Therapeut, Targ, and Develp.*

You D, Kim Y, Jang M, Lee C, Jeong IG, Cho Y, Hwang J, Hong J, Ahn H, and Kim C (2015) KML001 Induces Apoptosis and Autophagic Cell Death in Prostate Cancer Cells via Oxidative Stress Pathway. *PLoS ONE* 10(9): e0137589.

Zhang Y, Wei Z, Liu W, Wang J, He X, Huang H, Zhang J, and Yang Z (2017) Melatonin protects against arsenic trioxide-induced liver injury by the upregulation of Nrf2 expression through the activation of PI3K/AKT pathway. *Oncotarget* 8:3773-3780.

Zhang Y, Bhatia D, Xia H, Castranova V, Shi X, and Chen F (2006) Nucleolin links to arsenic-induced stabilization of GADD45a mRNA. *Nucleic Acids Research* 34:485-495.

Zhao L and Vogt P (2008) Class I PI3K in oncogenic cellular transformation. *Oncogene* 27:5486-5496.
Figure legend

Figure 1. Graphical representation illustrating the role of the PI3K/AKT/mTOR pathway in promoting cellular growth.
| Arsenic compound | Treatment | Cell Type | Technique platform | Pathway Effect | Tissue type | Reference |
|------------------|-----------|-----------|--------------------|----------------|-------------|-----------|
| Arsenite (As 3+) | 1.25 uM for 72 hours | JB6 Cl41 | Cell proliferation, cell cycle, gene reporter, PI-3 kinase assay, western blotting, cyclin D1 expression assay, | Activated PI3K and AKT | Epidermis | Ouyang et al. 2005 |
| NaAsO2 | 0,0.25,1, 5 uM for 26 weeks | BEAS-2B | Cell proliferation, soft agar, immunoblotting, ROS detection, | Activated AKT and mTOR | Lung | Carpenter et al. 2011 |
| AsCl3 | 10uM 0-16 hr | BEAS-2B | Western blotting, ELISA, cell migration | Activated AKT | Lung | Liu et al. 2012; |
| AsCl3 | 0-20uM 6-12 hr | BEAS-2B | Western blotting, rt-PCR, reporter assay, cell proliferation, transformation assay, enzyme-linked immunosorbant assay | Activated AKT | Lung | Beezhold et al. 2011 |
| AsCl3 | 0-20uM of arsenic chloride for up to 20 | BEAS-2B | RT-PCR, qPCR, RNA immunoprecipitation, immunofluorescence | Activated AKT | Lung | Zhang et al. 2006 |
| NaAsO2 | 2.5uM for 6 weeks | HBEC | Cell migration, invasion, western blotting, immunofluorescence | Activated AKT | Lung | Wang et al. 2012 |
| NaAsO2 | 0-20 uM for 6hrs | A375 | Western blotting, | Activated AKT | Skin | Li et al., 2015 |
| C₆AsNH₄O₆ | 1.0 µmol/L | Vascular endothelial cells male Wistar rats and C57BL/6 mice | MTT, cell proliferation, migration, tube formation, xenograft, immunohistochemical staining, westernblotting | Activated PI3K and AKT | Thoracic aorta | Wang et al., 2016 |
| NaAsO2 | 0,1,2,4,8,10 uM | SV-HUC-1 | RT-PCR, western blotting, elisa, | Activated PI3K and AKT | Ureter | Wang et al., 2013 |
| Arsenic compound | Treatment | Cell Type | Technique platform | Pathway Effect | Tissue type | Reference |
|------------------|-----------|-----------|--------------------|----------------|-------------|-----------|
| NaAsO2           | 0-2 uM for 7 days | 3T3-L1    | qRT-PCR, western blotting, immunofluorescence, | Inactivation of AKT | Adipocytes | Xue et al. 2011 |
| As₂O₃            | 0-10uM for 48 hrs or 5uM for up to 72 hrs | SW1353 | MTT, Western blotting, cell viability, clone formation, apoptosis, immunofluorescence, | Inactivation of AKT and mTOR | Chondrosarcoma | Jiao et al. 2015 |
| As₄O₆            | 1uM for 48 hrs | SW620 | Cell viability, ROS generation, cell cycle, nuclear staining, western blotting, inhibitors assay | Decreased PI3K/AKT | Colorectal cancer | Nagappan et al., 2017 |
| As₂O₃            | 0-16 uM for 24 hrs | SGC-7901 | Cell viability, mitochondrial membrane potential, apoptosis, western blotting | Inactivation of AKT | Gastric cancer | Gao et al. 2014 |
| As₂O₃            | 3mg/kg for 7 days | Male Wistar rats | Histological analysis, western blotting | Inactivation of PI3K and AKT | Liver | Zhang et al., 2017 |
| NA               | NA       | U937      | NA | Inactivation of AKT | Myeloid cancer | Choi et al. 2012 |
| As₂O₃            | 1 uM for NB4 and 4uM for THP1 cells for 4 hrs | NB4, THP1 | Flow cytometry, cell proliferation, viability, apoptosis, necrosis, ROS and GSH level, immunoblotting | ATO alone has no effect on AKT, only with 2-DG (2-deoxy-d-glucose) | Myeloid cancer | Estan et al., 2012 |
| As₂O₃            | 1uM for 24 hrs in NB4 cells and 10uM for 16 hrs in MGC803 cells | NB4 and MGC803 | Cell viability, cell cycle, western blotting | Inactivation of PI3K and AKT | Gastric and myeloid cancer | Li et al., 2009 |
| Compound | Concentration | Cell Lines | Assays | Inactivation | Tumor Type | Reference |
|----------|---------------|------------|--------|-------------|------------|-----------|
| As₂S₂    | 3.02uM to 13.06uM for 24h or 48hr treatment | 143B, MG-63, U-2OS, and HOS | Cell viability, clone formation, cell cycle, apoptosis, histopathology, immunohistochemistry, human osteosarcoma xenograft, western blotting, ROS generation | Inactivation of AKT and mTOR | Osteosarcoma | Wang et al. 2017 |
| As₂O₃    | 3uM for 48 hrs | B-CLL | Cell apoptosis, ROS, western blotting | Inactivation of PI3K and AKT | Peripheral blood | Redondo-Muñoz et al. 2010 |
Figure 1. Overview of arsenic-elicited PI3K/AKT/mTOR pathway activation and subsequent increase in cell growth.